morphine high potency injection (Astramorph, Duramorph, Infumorph, AVINza) (cont.)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
Patients may also develop anemia with intrathecal injection, and pain at the injection site. The elderly may be more sensitive to adverse effects. Morphine has the potential to be habit forming. Tolerance and physical and psychological dependence may occur with prolonged use. Seizures may result from high doses. Overdoses may cause respiratory depression, coma, and death.
GENERIC AVAILABLE: Yes
PREPARATIONS: Solution 0.5, 2, 4, 5, 8, 10, 15, 25, and 50 mg/mL in 1, 2, 10, 20, 30, 50, and 250 mL ampules or vials. There is a preservative-free formulation for intrathecal and epidural (spinal) administration.
STORAGE: Morphine injection solution should be protected from light and stored at room temperature, between 15 C to 30 C (59 F to 86 F).
DOSING: Dosing is specific to the route of administration. In adults (at least 18 years of age) the initial intravenous dose should be 2 to 10 mg per 70 kg of body weight over 24 hours. For epidural administration, 5 mg may be administered initially, with a maximum dose of 10 mg over 24 hours. Initial dosing for intrathecal administration should be 0.2 to 1 mg over 24 hours.
Fluoxetine (Prozac) may increase blood levels and the effect of morphine leading to increased side effects.
Morphine should also be avoided in patients treated with monoamine oxidase inhibitors (MAOI) due to enhance toxicity of morphine including confusion, high blood pressure, tremor, hyperactivity, coma, and death. Drugs in this class include isocarboxazid (Marplan), phenelzine (Nardil), tranylcypromine (Parnate), selegiline (Eldepryl), and procarbazine (Matulane), and linezolid (Zyvox). Morphine should not be administered within 14 days of stopping an MAOI.
PREGNANCY: Morphine injection should only be given to pregnant women when no other method of controlling pain is available and there are methods to monitor the fetus. Newborns may exhibit withdrawal symptoms if chronic dosing is used.
NURSING MOTHERS: Morphine is excreted in breast milk, however, the American Academy of Pediatrics committee states that it is safe to use while nursing
REFERENCE: FDA Prescribing Information
Medically Reviewed by a Doctor on 3/19/2015
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions